Global Disitamab Vedotin Market Growth 2026-2032

October 2026 | 85 pages | ID: G780100F4F5CEN
LP Information

US$ 3,660.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The global Disitamab Vedotin market size is predicted to grow from US$ 150 million in 2025 to US$ 530 million in 2032; it is expected to grow at a CAGR of 16.9% from 2026 to 2032.

Disitamab Vedotin is a human epidermal growth factor receptor 2-directed antibody-drug conjugate composed of a HER2-specific humanized monoclonal antibody, a protease-cleavable linker, and the microtubule-disrupting payload monomethyl auristatin E. After binding to HER2-expressing tumor cells, the antibody-drug conjugate is internalized and releases MMAE, resulting in microtubule inhibition, cell-cycle arrest, apoptosis, and a potential bystander-killing effect on adjacent tumor cells. The commercial product is supplied as a lyophilized formulation for intravenous infusion, with 60 mg per vial representing the principal marketed presentation. Its approved applications cover HER2-expressing locally advanced or metastatic gastric and gastroesophageal junction cancer, urothelial carcinoma, and advanced breast cancer with liver metastases. This study analyzes Disitamab Vedotin by indication, treatment line, sales channel, and end user, focusing on commercial product sales through hospitals, cancer centers, pharmaceutical distributors, and authorized specialty pharmacy channels.

Key Findings

Disitamab Vedotin sales volume reached approximately 301.9 thousand vials in 2025

China accounted for substantially all commercial product sales in 2025

The product had five approved indications in China by April 2026

Commercial access covered more than 1,050 hospitals in China by the end of 2025

RemeGen remains the sole confirmed commercial manufacturer of the marketed product

Market Trends

The Disitamab Vedotin market is shifting from a later-line, monotherapy-focused product toward a broader multi-indication and combination-treatment franchise. The original commercial base was built through later-line HER2-overexpressing gastric and urothelial cancer indications, followed by expansion into HER2-positive and HER2-low advanced breast cancer with liver metastases. Approval of the combination with toripalimab for first-line HER2-expressing locally advanced or metastatic urothelial carcinoma in April 2026 moved the product into an earlier and larger treatment population. Product development is also expanding beyond strict HER2 overexpression toward broader HER2 expression levels, increasing the importance of standardized immunohistochemistry testing and patient stratification. The longer-term direction is expected to emphasize earlier treatment lines, immunotherapy combinations, broader HER2-defined populations, and selected international registration opportunities rather than relying solely on additional later-line monotherapy indications.

Market Dynamics

Drivers

Market expansion is supported by the continuing unmet need in advanced gastric cancer, urothelial carcinoma, and breast cancer with liver metastases, particularly among patients who have progressed after established systemic treatments. The product's movement from later-line monotherapy into first-line combination treatment materially enlarges the addressable patient population. Expansion from HER2-positive or overexpressing tumors into HER2-low disease further broadens the clinically eligible population. Commercial growth is also supported by inclusion of established indications in China's medical insurance system, increasing physician familiarity with antibody-drug conjugates, and the reuse of an oncology commercial network that had covered more than 1,050 hospitals by the end of 2025.

Restraints

The market remains constrained by reimbursement-driven price pressure, intravenous administration requirements, HER2 testing, treatment-related toxicity management, and competition from other HER2-directed therapies and antibody-drug conjugates. Commercial uptake varies across indications because eligible patient populations, treatment sequencing, diagnostic thresholds, and combination-therapy requirements differ materially. New indications can increase treatment volume while reducing average net revenue per vial if reimbursement negotiations, hospital tenders, or channel discounts intensify. International expansion is also limited by the time and cost required for global clinical development, regulatory submissions, manufacturing validation, and market access, while commercial revenue remains concentrated in China.

Opportunities

The strongest near-term opportunity lies in converting recently approved breast cancer and first-line urothelial carcinoma indications into hospital access and routine clinical use. The first-line urothelial cancer combination creates a larger treatment opportunity than the original later-line indication, while the HER2-low breast cancer label extends the product beyond conventionally HER2-positive populations. Further opportunities may arise from first-line gastric cancer combinations, additional breast cancer settings, perioperative treatment, and selected HER2-expressing solid tumors. International development led through the Pfizer collaboration provides additional upside, with first-line HER2-expressing metastatic urothelial cancer remaining in Phase III development as of May 2026.

Challenges

The principal long-term challenge is translating multiple regulatory approvals into sustained commercial adoption while maintaining clear clinical differentiation. Disitamab Vedotin competes at the treatment-pathway level with other HER2 ADCs, monoclonal antibodies, tyrosine kinase inhibitors, chemotherapy, immunotherapy combinations, and alternative urothelial cancer ADCs. Variations in HER2 testing standards and interpretation may affect patient identification across tumor types and hospitals. The product also depends on a concentrated manufacturing and commercialization structure, while ex-China development remains subject to clinical, regulatory, pricing, and strategic portfolio risks. Pfizer discontinued one broader HER2-expressing solid-tumor Phase II program in 2026 while retaining prioritized urothelial cancer programs, illustrating the need for a selective rather than uniform international development strategy.

Industry Chain Analysis

The upstream industry chain includes HER2-specific monoclonal antibody production, MMAE payload and cleavable-linker synthesis, conjugation reagents, cell-culture media, chromatography materials, single-use bioprocessing systems, analytical reagents, sterile containers, and cold-chain packaging. Manufacturing involves antibody expression and purification, linker-payload preparation, controlled antibody-drug conjugation, removal of free payload, formulation, aseptic filling, lyophilization, and batch-release testing. Critical quality attributes include antibody identity and purity, drug-to-antibody ratio, conjugation consistency, free-payload levels, aggregation, biological potency, sterility, and stability. These requirements create high process-development, analytical, quality-assurance, and regulatory barriers.

The midstream segment consists of product research, clinical development, commercial manufacturing, regulatory registration, market access, medical affairs, and commercialization. RemeGen controls the originator technology, marketed-product manufacturing, Chinese regulatory approvals, and domestic commercialization, while Pfizer holds development and commercialization rights in licensed ex-RemeGen territories and is advancing selected international clinical programs. The downstream chain comprises national and regional pharmaceutical distributors, DTP and specialty pharmacies, hospital pharmacies, general hospitals, cancer hospitals, oncology departments, infusion centers, and diagnostic laboratories. Value is concentrated in proprietary ADC technology, clinical evidence, manufacturing consistency, approved indications, reimbursement access, hospital coverage, and the ability to identify eligible patients through standardized HER2 testing.

Segment Insights

By Indication, commercial demand is divided among gastric and gastroesophageal junction cancer, urothelial carcinoma, and breast cancer. Gastric cancer and later-line urothelial carcinoma formed the original commercial base, while breast cancer and first-line urothelial carcinoma represent the principal incremental opportunities. The breast cancer segment has expanded from HER2-positive disease to HER2-low disease with liver metastases, while the urothelial carcinoma segment now covers both later-line monotherapy and first-line combination treatment. These changes are expected to shift the revenue structure toward larger but more competitive patient populations.

By Treatment Line, the market now spans first-line, second-line, and third-line or later treatment. Third-line gastric cancer and previously treated urothelial carcinoma established the initial market, while the first-line urothelial carcinoma combination is expected to become a major volume-growth driver. By Sales Channel, the product reaches patients through direct institutional sales, pharmaceutical distributors, DTP and specialty pharmacies, and other authorized channels. By End User, cancer hospitals and large general hospitals account for most use because treatment requires HER2 testing, intravenous infusion, oncology expertise, and adverse-event management; other qualified medical institutions represent a smaller supplementary segment.

Downstream Market Opportunities

The largest downstream opportunities are concentrated in tertiary general hospitals, cancer hospitals, breast cancer centers, gastrointestinal oncology departments, and urologic oncology centers. These institutions have the diagnostic and treatment capabilities required to perform HER2 testing, determine treatment line, manage combination regimens, and monitor ADC-related adverse events. Continued hospital listing and broader specialist education can increase use beyond leading urban centers, while DTP and specialty pharmacy networks can support dual-channel reimbursement, out-of-hospital dispensing, patient services, and treatment continuity. New opportunities are particularly significant in hospitals that already use the product for one tumor type and can extend adoption to newly approved breast cancer or first-line urothelial carcinoma indications through the same pharmacy, medical affairs, and infusion infrastructure.

Regional Insights

China remains the only established commercial market and accounted for substantially all Disitamab Vedotin product sales in 2025. The product benefited from continued volume growth, expanding indications, medical insurance coverage for established indications, and an oncology commercial team serving more than 1,050 hospitals. Regional adoption within China remains uneven, with leading cancer hospitals and tertiary general hospitals adopting new indications faster than lower-tier institutions. Future domestic growth will depend on hospital listing for recently approved indications, local reimbursement implementation, HER2 testing capacity, and the penetration of first-line combination treatment beyond major oncology centers.

Outside China, Disitamab Vedotin remains a clinical-development asset rather than an established commercial product. Pfizer's May 2026 pipeline included Phase III development in first-line HER2-expressing metastatic urothelial cancer and Phase II development in later-line HER2-expressing metastatic urothelial cancer. North America, Europe, Japan, and other Asia-Pacific markets therefore represent probability-adjusted future opportunities rather than current revenue bases. International commercialization will depend on clinical outcomes, regulatory strategy, diagnostic standards, competitive positioning, pricing, and the timing of market authorization.

Competitive Landscape Analysis

The Disitamab Vedotin market has an exclusive originator and licensing structure rather than a conventional multi-manufacturer competitive landscape. RemeGen is the sole confirmed commercial manufacturer, marketing authorization holder, and Chinese commercialization company, while Pfizer holds licensed development and commercialization rights in designated ex-China territories through the rights previously held by Seagen. The two companies therefore occupy complementary positions within the same product-rights system and should not be treated as manufacturers of competing versions. Competitive pressure comes from other HER2-directed ADCs, HER2 monoclonal antibodies, tyrosine kinase inhibitors, immunotherapy combinations, chemotherapy, and alternative ADCs used in urothelial carcinoma. RemeGen's competitive position is supported by first-mover status in China, five approved indications, medical insurance access for established indications, a broad hospital network, and expansion into HER2-low and first-line combination settings. Longer-term competitiveness will depend on indication conversion, pricing discipline, manufacturing scalability, HER2-testing standardization, clinical differentiation from competing ADCs, and successful international development through Pfizer.

Report Scope

LP Information, Inc. (LPI) ' newest research report, the “Disitamab Vedotin Industry Forecast” looks at past sales and reviews total world Disitamab Vedotin sales in 2025, providing a comprehensive analysis by region and market sector of projected Disitamab Vedotin sales for 2026 through 2032. With Disitamab Vedotin sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Disitamab Vedotin industry.

This Insight Report provides a comprehensive analysis of the global Disitamab Vedotin landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Disitamab Vedotin portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Disitamab Vedotin market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Disitamab Vedotin and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Disitamab Vedotin.

This report presents a comprehensive overview, market shares, and growth opportunities of Disitamab Vedotin market by product type, application, key manufacturers and key regions and countries.

Market Segmentation

Segmentation by Type:

  • Gastric and Gastroesophageal Junction Cancer
  • Urothelial Carcinoma
  • Breast Cancer

Segmentation by Treatment Line:

  • First-line Treatment
  • Second-line Treatment
  • Third-line or Later Treatment

Segmentation by Sales Channel:

  • Direct Sales
  • Distributor Sales

Segmentation by Application:

  • General Hospitals
  • Cancer Hospitals
  • Other

This report also splits the market by region:

  • Americas
    • United States
    • Canada
    • Mexico
    • Brazil
  • APAC
    • China
    • Japan
    • Korea
    • Southeast Asia
    • India
    • Australia
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Russia
  • Middle East & Africa
    • Egypt
    • South Africa
    • Israel
    • Turkey
    • GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
  • RemeGen
  • Pfizer

Key Questions Addressed in this Report

  • What is the 10-year outlook for the global Disitamab Vedotin market?
  • What factors are driving Disitamab Vedotin market growth, globally and by region?
  • Which technologies are poised for the fastest growth by market and region?
  • How do Disitamab Vedotin market opportunities vary by end market size?
  • How does Disitamab Vedotin break out by Type, by Application?
1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Disitamab Vedotin Annual Sales 2021-2032
  2.1.2 World Current & Future Analysis for Disitamab Vedotin by Geographic Region, 2021, 2025 & 2032
  2.1.3 World Current & Future Analysis for Disitamab Vedotin by Country/Region, 2021, 2025 & 2032
2.2 Disitamab Vedotin Segment by Type
  2.2.1 Gastric and Gastroesophageal Junction Cancer
  2.2.2 Urothelial Carcinoma
  2.2.3 Breast Cancer
  2.2.4 Disitamab Vedotin Sales by Type
    2.2.4.1 Global Disitamab Vedotin Sales Market Share by Type (2021-2026)
    2.2.4.2 Global Disitamab Vedotin Revenue and Market Share by Type (2021-2026)
    2.2.4.3 Global Disitamab Vedotin Sale Price by Type (2021-2026)
2.3 Disitamab Vedotin Segment by Treatment Line
  2.3.1 First-line Treatment
  2.3.2 Second-line Treatment
  2.3.3 Third-line or Later Treatment
  2.3.4 Disitamab Vedotin Sales by Treatment Line
    2.3.4.1 Global Disitamab Vedotin Sales Market Share by Treatment Line (2021-2026)
    2.3.4.2 Global Disitamab Vedotin Revenue and Market Share by Treatment Line (2021-2026)
    2.3.4.3 Global Disitamab Vedotin Sale Price by Treatment Line (2021-2026)
2.4 Disitamab Vedotin Segment by Sales Channel
  2.4.1 Direct Sales
  2.4.2 Distributor Sales
  2.4.3 Disitamab Vedotin Sales by Sales Channel
    2.4.3.1 Global Disitamab Vedotin Sales Market Share by Sales Channel (2021-2026)
    2.4.3.2 Global Disitamab Vedotin Revenue and Market Share by Sales Channel (2021-2026)
    2.4.3.3 Global Disitamab Vedotin Sale Price by Sales Channel (2021-2026)
2.5 Disitamab Vedotin Segment by Application
  2.5.1 General Hospitals
  2.5.2 Cancer Hospitals
  2.5.3 Other
  2.5.4 Disitamab Vedotin Sales by Application
    2.5.4.1 Global Disitamab Vedotin Sale Market Share by Application (2021-2026)
    2.5.4.2 Global Disitamab Vedotin Revenue and Market Share by Application (2021-2026)
    2.5.4.3 Global Disitamab Vedotin Sale Price by Application (2021-2026)

3 GLOBAL BY COMPANY

3.1 Global Disitamab Vedotin Breakdown Data by Company
  3.1.1 Global Disitamab Vedotin Annual Sales by Company (2021-2026)
  3.1.2 Global Disitamab Vedotin Sales Market Share by Company (2021-2026)
3.2 Global Disitamab Vedotin Annual Revenue by Company (2021-2026)
  3.2.1 Global Disitamab Vedotin Revenue by Company (2021-2026)
  3.2.2 Global Disitamab Vedotin Revenue Market Share by Company (2021-2026)
3.3 Global Disitamab Vedotin Sale Price by Company
3.4 Key Manufacturers Disitamab Vedotin Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Disitamab Vedotin Product Location Distribution
  3.4.2 Players Disitamab Vedotin Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy

4 WORLD HISTORIC REVIEW FOR DISITAMAB VEDOTIN BY GEOGRAPHIC REGION

4.1 World Historic Disitamab Vedotin Market Size by Geographic Region (2021-2026)
  4.1.1 Global Disitamab Vedotin Annual Sales by Geographic Region (2021-2026)
  4.1.2 Global Disitamab Vedotin Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Disitamab Vedotin Market Size by Country/Region (2021-2026)
  4.2.1 Global Disitamab Vedotin Annual Sales by Country/Region (2021-2026)
  4.2.2 Global Disitamab Vedotin Annual Revenue by Country/Region (2021-2026)
4.3 Americas Disitamab Vedotin Sales Growth
4.4 APAC Disitamab Vedotin Sales Growth
4.5 Europe Disitamab Vedotin Sales Growth
4.6 Middle East & Africa Disitamab Vedotin Sales Growth

5 AMERICAS

5.1 Americas Disitamab Vedotin Sales by Country
  5.1.1 Americas Disitamab Vedotin Sales by Country (2021-2026)
  5.1.2 Americas Disitamab Vedotin Revenue by Country (2021-2026)
5.2 Americas Disitamab Vedotin Sales by Type (2021-2026)
5.3 Americas Disitamab Vedotin Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Disitamab Vedotin Sales by Region
  6.1.1 APAC Disitamab Vedotin Sales by Region (2021-2026)
  6.1.2 APAC Disitamab Vedotin Revenue by Region (2021-2026)
6.2 APAC Disitamab Vedotin Sales by Type (2021-2026)
6.3 APAC Disitamab Vedotin Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Disitamab Vedotin by Country
  7.1.1 Europe Disitamab Vedotin Sales by Country (2021-2026)
  7.1.2 Europe Disitamab Vedotin Revenue by Country (2021-2026)
7.2 Europe Disitamab Vedotin Sales by Type (2021-2026)
7.3 Europe Disitamab Vedotin Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Disitamab Vedotin by Country
  8.1.1 Middle East & Africa Disitamab Vedotin Sales by Country (2021-2026)
  8.1.2 Middle East & Africa Disitamab Vedotin Revenue by Country (2021-2026)
8.2 Middle East & Africa Disitamab Vedotin Sales by Type (2021-2026)
8.3 Middle East & Africa Disitamab Vedotin Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Disitamab Vedotin
10.3 Manufacturing Process Analysis of Disitamab Vedotin
10.4 Industry Chain Structure of Disitamab Vedotin

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Disitamab Vedotin Distributors
11.3 Disitamab Vedotin Customer

12 WORLD FORECAST REVIEW FOR DISITAMAB VEDOTIN BY GEOGRAPHIC REGION

12.1 Global Disitamab Vedotin Market Size Forecast by Region
  12.1.1 Global Disitamab Vedotin Forecast by Region (2027-2032)
  12.1.2 Global Disitamab Vedotin Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Disitamab Vedotin Forecast by Type (2027-2032)
12.7 Global Disitamab Vedotin Forecast by Application (2027-2032)

13 KEY PLAYERS ANALYSIS

13.1 RemeGen
  13.1.1 RemeGen Company Information
  13.1.2 RemeGen Disitamab Vedotin Product Portfolios and Specifications
  13.1.3 RemeGen Disitamab Vedotin Sales, Revenue, Price and Gross Margin (2021-2026)
  13.1.4 RemeGen Main Business Overview
  13.1.5 RemeGen Latest Developments
13.2 Pfizer
  13.2.1 Pfizer Company Information
  13.2.2 Pfizer Disitamab Vedotin Product Portfolios and Specifications
  13.2.3 Pfizer Disitamab Vedotin Sales, Revenue, Price and Gross Margin (2021-2026)
  13.2.4 Pfizer Main Business Overview
  13.2.5 Pfizer Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES

Table 1. Disitamab Vedotin Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Disitamab Vedotin Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Gastric and Gastroesophageal Junction Cancer
Table 4. Major Players of Urothelial Carcinoma
Table 5. Major Players of Breast Cancer
Table 6. Global Disitamab Vedotin Sales by Type (2021-2026) & (K Units)
Table 7. Global Disitamab Vedotin Sales Market Share by Type (2021-2026)
Table 8. Global Disitamab Vedotin Revenue by Type (2021-2026) & ($ million)
Table 9. Global Disitamab Vedotin Revenue Market Share by Type (2021-2026)
Table 10. Global Disitamab Vedotin Sale Price by Type (2021-2026) & (US$/Unit)
Table 11. Major Players of First-line Treatment
Table 12. Major Players of Second-line Treatment
Table 13. Major Players of Third-line or Later Treatment
Table 14. Global Disitamab Vedotin Sales by Treatment Line (2021-2026) & (K Units)
Table 15. Global Disitamab Vedotin Sales Market Share by Treatment Line (2021-2026)
Table 16. Global Disitamab Vedotin Revenue by Treatment Line (2021-2026) & ($ million)
Table 17. Global Disitamab Vedotin Revenue Market Share by Treatment Line (2021-2026)
Table 18. Global Disitamab Vedotin Sale Price by Treatment Line (2021-2026) & (US$/Unit)
Table 19. Major Players of Direct Sales
Table 20. Major Players of Distributor Sales
Table 21. Global Disitamab Vedotin Sales by Sales Channel (2021-2026) & (K Units)
Table 22. Global Disitamab Vedotin Sales Market Share by Sales Channel (2021-2026)
Table 23. Global Disitamab Vedotin Revenue by Sales Channel (2021-2026) & ($ million)
Table 24. Global Disitamab Vedotin Revenue Market Share by Sales Channel (2021-2026)
Table 25. Global Disitamab Vedotin Sale Price by Sales Channel (2021-2026) & (US$/Unit)
Table 26. Global Disitamab Vedotin Sale by Application (2021-2026) & (K Units)
Table 27. Global Disitamab Vedotin Sale Market Share by Application (2021-2026)
Table 28. Global Disitamab Vedotin Revenue by Application (2021-2026) & ($ million)
Table 29. Global Disitamab Vedotin Revenue Market Share by Application (2021-2026)
Table 30. Global Disitamab Vedotin Sale Price by Application (2021-2026) & (US$/Unit)
Table 31. Global Disitamab Vedotin Sales by Company (2021-2026) & (K Units)
Table 32. Global Disitamab Vedotin Sales Market Share by Company (2021-2026)
Table 33. Global Disitamab Vedotin Revenue by Company (2021-2026) & ($ millions)
Table 34. Global Disitamab Vedotin Revenue Market Share by Company (2021-2026)
Table 35. Global Disitamab Vedotin Sale Price by Company (2021-2026) & (US$/Unit)
Table 36. Key Manufacturers Disitamab Vedotin Producing Area Distribution and Sales Area
Table 37. Players Disitamab Vedotin Products Offered
Table 38. Disitamab Vedotin Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 39. New Products and Potential Entrants
Table 40. Market M&A Activity & Strategy
Table 41. Global Disitamab Vedotin Sales by Geographic Region (2021-2026) & (K Units)
Table 42. Global Disitamab Vedotin Sales Market Share Geographic Region (2021-2026)
Table 43. Global Disitamab Vedotin Revenue by Geographic Region (2021-2026) & ($ millions)
Table 44. Global Disitamab Vedotin Revenue Market Share by Geographic Region (2021-2026)
Table 45. Global Disitamab Vedotin Sales by Country/Region (2021-2026) & (K Units)
Table 46. Global Disitamab Vedotin Sales Market Share by Country/Region (2021-2026)
Table 47. Global Disitamab Vedotin Revenue by Country/Region (2021-2026) & ($ millions)
Table 48. Global Disitamab Vedotin Revenue Market Share by Country/Region (2021-2026)
Table 49. Americas Disitamab Vedotin Sales by Country (2021-2026) & (K Units)
Table 50. Americas Disitamab Vedotin Sales Market Share by Country (2021-2026)
Table 51. Americas Disitamab Vedotin Revenue by Country (2021-2026) & ($ millions)
Table 52. Americas Disitamab Vedotin Sales by Type (2021-2026) & (K Units)
Table 53. Americas Disitamab Vedotin Sales by Application (2021-2026) & (K Units)
Table 54. APAC Disitamab Vedotin Sales by Region (2021-2026) & (K Units)
Table 55. APAC Disitamab Vedotin Sales Market Share by Region (2021-2026)
Table 56. APAC Disitamab Vedotin Revenue by Region (2021-2026) & ($ millions)
Table 57. APAC Disitamab Vedotin Sales by Type (2021-2026) & (K Units)
Table 58. APAC Disitamab Vedotin Sales by Application (2021-2026) & (K Units)
Table 59. Europe Disitamab Vedotin Sales by Country (2021-2026) & (K Units)
Table 60. Europe Disitamab Vedotin Revenue by Country (2021-2026) & ($ millions)
Table 61. Europe Disitamab Vedotin Sales by Type (2021-2026) & (K Units)
Table 62. Europe Disitamab Vedotin Sales by Application (2021-2026) & (K Units)
Table 63. Middle East & Africa Disitamab Vedotin Sales by Country (2021-2026) & (K Units)
Table 64. Middle East & Africa Disitamab Vedotin Revenue Market Share by Country (2021-2026)
Table 65. Middle East & Africa Disitamab Vedotin Sales by Type (2021-2026) & (K Units)
Table 66. Middle East & Africa Disitamab Vedotin Sales by Application (2021-2026) & (K Units)
Table 67. Key Market Drivers & Growth Opportunities of Disitamab Vedotin
Table 68. Key Market Challenges & Risks of Disitamab Vedotin
Table 69. Key Industry Trends of Disitamab Vedotin
Table 70. Disitamab Vedotin Raw Material
Table 71. Key Suppliers of Raw Materials
Table 72. Disitamab Vedotin Distributors List
Table 73. Disitamab Vedotin Customer List
Table 74. Global Disitamab Vedotin Sales Forecast by Region (2027-2032) & (K Units)
Table 75. Global Disitamab Vedotin Revenue Forecast by Region (2027-2032) & ($ millions)
Table 76. Americas Disitamab Vedotin Sales Forecast by Country (2027-2032) & (K Units)
Table 77. Americas Disitamab Vedotin Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 78. APAC Disitamab Vedotin Sales Forecast by Region (2027-2032) & (K Units)
Table 79. APAC Disitamab Vedotin Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 80. Europe Disitamab Vedotin Sales Forecast by Country (2027-2032) & (K Units)
Table 81. Europe Disitamab Vedotin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 82. Middle East & Africa Disitamab Vedotin Sales Forecast by Country (2027-2032) & (K Units)
Table 83. Middle East & Africa Disitamab Vedotin Revenue Forecast by Country (2027-2032) & ($ millions)
Table 84. Global Disitamab Vedotin Sales Forecast by Type (2027-2032) & (K Units)
Table 85. Global Disitamab Vedotin Revenue Forecast by Type (2027-2032) & ($ millions)
Table 86. Global Disitamab Vedotin Sales Forecast by Application (2027-2032) & (K Units)
Table 87. Global Disitamab Vedotin Revenue Forecast by Application (2027-2032) & ($ millions)
Table 88. RemeGen Basic Information, Disitamab Vedotin Manufacturing Base, Sales Area and Its Competitors
Table 89. RemeGen Disitamab Vedotin Product Portfolios and Specifications
Table 90. RemeGen Disitamab Vedotin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 91. RemeGen Main Business
Table 92. RemeGen Latest Developments
Table 93. Pfizer Basic Information, Disitamab Vedotin Manufacturing Base, Sales Area and Its Competitors
Table 94. Pfizer Disitamab Vedotin Product Portfolios and Specifications
Table 95. Pfizer Disitamab Vedotin Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 96. Pfizer Main Business
Table 97. Pfizer Latest Developments

LIST OF FIGURES

Figure 1. Picture of Disitamab Vedotin
Figure 2. Disitamab Vedotin Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Disitamab Vedotin Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Disitamab Vedotin Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Disitamab Vedotin Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Disitamab Vedotin Sales Market Share by Country/Region (2025)
Figure 10. Disitamab Vedotin Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Gastric and Gastroesophageal Junction Cancer
Figure 12. Product Picture of Urothelial Carcinoma
Figure 13. Product Picture of Breast Cancer
Figure 14. Global Disitamab Vedotin Sales Market Share by Type in 2026
Figure 15. Global Disitamab Vedotin Revenue Market Share by Type (2021-2026)
Figure 16. Product Picture of First-line Treatment
Figure 17. Product Picture of Second-line Treatment
Figure 18. Product Picture of Third-line or Later Treatment
Figure 19. Global Disitamab Vedotin Sales Market Share by Treatment Line in 2026
Figure 20. Global Disitamab Vedotin Revenue Market Share by Treatment Line (2021-2026)
Figure 21. Product Picture of Direct Sales
Figure 22. Product Picture of Distributor Sales
Figure 23. Global Disitamab Vedotin Sales Market Share by Sales Channel in 2026
Figure 24. Global Disitamab Vedotin Revenue Market Share by Sales Channel (2021-2026)
Figure 25. Disitamab Vedotin Consumed in General Hospitals
Figure 26. Global Disitamab Vedotin Market: General Hospitals (2021-2026) & (K Units)
Figure 27. Disitamab Vedotin Consumed in Cancer Hospitals
Figure 28. Global Disitamab Vedotin Market: Cancer Hospitals (2021-2026) & (K Units)
Figure 29. Disitamab Vedotin Consumed in Other
Figure 30. Global Disitamab Vedotin Market: Other (2021-2026) & (K Units)
Figure 31. Global Disitamab Vedotin Sale Market Share by Application (2025)
Figure 32. Global Disitamab Vedotin Revenue Market Share by Application in 2025
Figure 33. Disitamab Vedotin Sales by Company in 2025 (K Units)
Figure 34. Global Disitamab Vedotin Sales Market Share by Company in 2025
Figure 35. Disitamab Vedotin Revenue by Company in 2025 ($ millions)
Figure 36. Global Disitamab Vedotin Revenue Market Share by Company in 2025
Figure 37. Global Disitamab Vedotin Sales Market Share by Geographic Region (2021-2026)
Figure 38. Global Disitamab Vedotin Revenue Market Share by Geographic Region in 2025
Figure 39. Americas Disitamab Vedotin Sales 2021-2026 (K Units)
Figure 40. Americas Disitamab Vedotin Revenue 2021-2026 ($ millions)
Figure 41. APAC Disitamab Vedotin Sales 2021-2026 (K Units)
Figure 42. APAC Disitamab Vedotin Revenue 2021-2026 ($ millions)
Figure 43. Europe Disitamab Vedotin Sales 2021-2026 (K Units)
Figure 44. Europe Disitamab Vedotin Revenue 2021-2026 ($ millions)
Figure 45. Middle East & Africa Disitamab Vedotin Sales 2021-2026 (K Units)
Figure 46. Middle East & Africa Disitamab Vedotin Revenue 2021-2026 ($ millions)
Figure 47. Americas Disitamab Vedotin Sales Market Share by Country in 2025
Figure 48. Americas Disitamab Vedotin Revenue Market Share by Country (2021-2026)
Figure 49. Americas Disitamab Vedotin Sales Market Share by Type (2021-2026)
Figure 50. Americas Disitamab Vedotin Sales Market Share by Application (2021-2026)
Figure 51. United States Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 52. Canada Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 53. Mexico Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 54. Brazil Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 55. APAC Disitamab Vedotin Sales Market Share by Region in 2025
Figure 56. APAC Disitamab Vedotin Revenue Market Share by Region (2021-2026)
Figure 57. APAC Disitamab Vedotin Sales Market Share by Type (2021-2026)
Figure 58. APAC Disitamab Vedotin Sales Market Share by Application (2021-2026)
Figure 59. China Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 60. Japan Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 61. South Korea Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 62. Southeast Asia Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 63. India Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 64. Australia Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 65. China Taiwan Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 66. Europe Disitamab Vedotin Sales Market Share by Country in 2025
Figure 67. Europe Disitamab Vedotin Revenue Market Share by Country (2021-2026)
Figure 68. Europe Disitamab Vedotin Sales Market Share by Type (2021-2026)
Figure 69. Europe Disitamab Vedotin Sales Market Share by Application (2021-2026)
Figure 70. Germany Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 71. France Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 72. UK Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 73. Italy Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 74. Russia Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 75. Middle East & Africa Disitamab Vedotin Sales Market Share by Country (2021-2026)
Figure 76. Middle East & Africa Disitamab Vedotin Sales Market Share by Type (2021-2026)
Figure 77. Middle East & Africa Disitamab Vedotin Sales Market Share by Application (2021-2026)
Figure 78. Egypt Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 79. South Africa Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 80. Israel Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 81. Turkey Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 82. GCC Countries Disitamab Vedotin Revenue Growth 2021-2026 ($ millions)
Figure 83. Manufacturing Cost Structure Analysis of Disitamab Vedotin in 2026
Figure 84. Manufacturing Process Analysis of Disitamab Vedotin
Figure 85. Industry Chain Structure of Disitamab Vedotin
Figure 86. Channels of Distribution
Figure 87. Global Disitamab Vedotin Sales Market Forecast by Region (2027-2032)
Figure 88. Global Disitamab Vedotin Revenue Market Share Forecast by Region (2027-2032)
Figure 89. Global Disitamab Vedotin Sales Market Share Forecast by Type (2027-2032)
Figure 90. Global Disitamab Vedotin Revenue Market Share Forecast by Type (2027-2032)
Figure 91. Global Disitamab Vedotin Sales Market Share Forecast by Application (2027-2032)
Figure 92. Global Disitamab Vedotin Revenue Market Share Forecast by Application (2027-2032)